Stanford University

Marius Wernig on why we need many stem cell approaches to new therapies

Last week we blogged about work by Marius Wernig of Stanford University, who has successfully converted human skin into nerves, skipping the step of first converting the cells into embryonic-like iPS cells.

Wernig is quoted in a Nature news story talking about whether the work could replace induced pluripotent stem (iPS) cells or embryonic stem cells:

CIRM grantees convert skin to nerves, a step toward therapies for neurological disease

Last year a group of CIRM grantees at Stanford University directly converted mouse skin cells into neurons, bypassing the need to first convert those cells into an embryonic-like state. Now they've gone a step farther, pulling off the same feat with human cells. They published the work in the May 26 Nature.

Krista Conger at Stanford University blogged about that work , quoting senior author Marius Wernig:

iPS cells reveal stem cell origin of disease

A new Nature paper from CIRM grantees at Stanford University once again shows the value of reprogrammed iPS cells in understanding disease. Scientists can't develop a therapy for a disease if they don't know what it is going wrong. In many cases, iPS cells have provided the first ever way of peering into diseased cells and finding which proteins and genes need fixing.

Celebrating National Cancer Research Month with a cancer stem cell round-up

In celebration of National Cancer Research Month, our colleagues at Sanford-Burnham Medical Research Institute have posted a series of blog entries about cancer research at their institute. The latest installment includes CIRM grantee Robert Wechsler-Reya, who moved to California from Duke University on a CIRM Research Leadership Award.

IVF embryo donation approach gives donors privacy, time

A new paper by CIRM grantees at Stanford University is reporting on an innovative way of ensuring that people considering donating left over in vitro fertilization embryos to research make the best possible decision for themselves. The paper was published on April 8 in Cell Stem Cell.

First patient from Geron spinal cord injury trial speaks up

A story by Rob Stein at the Washington Post is reporting that the first patient to participate in Geron's groundbreaking embryonic stem cell-based trial for spinal cord injury has come forward.

New disease-specific embryonic stem cell lines from Michigan

Stem cell scientists at the University of Michigan and in Detroit have created two embryonic stem cell lines that contain disease-causing mutations: Hemophilia B, a hereditary condition in which the blood does not clot properly and Charcot-Marie-Tooth disease, an inherited disorder leading to degeneration of muscles in the foot, lower leg and hand.

Parkinson's disease modeled for the first time in a lab dish

CIRM grantees at Stanford University and The Parkinson's Institute have an exciting Cell Stem Cell paper out today showing that they can mimic Parkinson's disease in a lab dish using reprogrammed iPS cells.

Reflecting on muscular dystrophy awareness week

This past week was muscular dystrophy awareness week, which seems like a short amount of time to focus on such a heartbreaking disease. One in every 3500 boys in the US develops that debilitating and fatal Duchenne muscular dystrophy (DMD) - the most common and serious form of muscular dystrophy - and there is no cure.

iPS cells lead to drug discovery for heart disease, autism up next

We've long claimed that one ideal role for iPS cells is modeling disease and screening drugs. In fact, we're so committed to that idea we produced a video about it with CIRM grantee Bruce Conklin at the Gladstone Institutes. Scientific American also has a story on disease model their March issue, available online.


Subscribe to RSS - Stanford University

© 2013 California Institute for Regenerative Medicine